Business Context and Reporting Period
This Form 8-K is a current report filed by OncoGenex Pharmaceuticals, Inc. (noting a discrepancy with the metadata company name "ACHIEVE LIFE SCIENCES, INC.") dated February 4, 2013, covering events occurring on January 31, 2013. The filing addresses significant changes in executive leadership and compensatory arrangements triggered by a personal relationship between the CEO and the CFO.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and separation agreements.
- Michelle Burris (Outgoing CFO): Monthly consultant retainer of approximately $34,000; potential incentive payment up to 40% of aggregate 2013 payments; potential lump sum severance of approximately $410,000 (or $511,000 in change of control scenarios).
- Susan Wyrick (Incoming Principal Accounting Officer): Annual base salary of $200,000; annual bonus up to 25% of base salary; one-time signing bonus of $5,000.
Material Changes
Effective February 1, 2013, Michelle Burris resigned as Principal Accounting Officer, Chief Financial Officer, Secretary, and Treasurer. She will serve as Executive Vice President of Operations until March 31, 2013, after which she will transition to a consultant role. Concurrently, Scott Cormack (CEO) was appointed as Principal Financial Officer, Secretary, and Treasurer. Susan Wyrick was appointed as Principal Accounting Officer.
Outlook, Risks, and Contingencies
The primary contingency involves the separation agreement with Ms. Burris, which includes specific payouts and accelerated vesting of equity awards contingent upon her release of claims against the Company. These benefits are forfeited if she terminates the consultancy early for convenience or if the Company terminates her for uncured breach. The filing notes no family relationships between the new appointees and existing directors or officers.
Investor Verification Checklist
- Verify the total cash and equity value of the separation package for Ms. Burris, including the potential $410,000 to $511,000 lump sum.
- Confirm the impact of the CFO departure on the company's financial reporting timeline and internal controls.
- Review the new employment agreement for Ms. Wyrick to understand the specific corporate milestones tied to her bonus structure.
- Assess the potential dilution from the accelerated vesting of Ms. Burris's stock options and restricted stock units.